مباشر

BioPharma DiveFDA delays decision on AstraZeneca breast cancer pill FierceBiotechKordata Dynamics launches with neural-focused AI clinical trial model Clinical OMICsDual CA19-9 Threshold Improves Risk Stratification in Pancreatic Cancer Clinical OMICsCD169-Positive Macrophages Attacking Melanoma Imaged in Living Tissue Clinical OMICsGuardant Nabs Key ACS Nod and Liquid Biopsy Approval Clinical OMICsAI Foundation Model Maps Tumor Mutations to Predict Cancer Therapy Response BioPharma DiveCardio drugmaker Kardigan plans to go public BioPharma DiveKailera’s three-pronged obesity shot shows promise in early trial BioPharma DiveApogee eczema drugs gets Blackstone backing, heads to Phase 3 Endpoints NewsAstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave Endpoints NewsApogee secures Blackstone capital to move Dupixent rival into Phase 3 Clinical OMICsPrecancerous Adenomas Alter Gut Microbiome for Long Period

Endpoints News ٢٧ مايو ٢٠٢٦

Apogee secures Blackstone capital to move Dupixent rival into Phase 3

The biggest question Apogee Therapeutics CEO Michael Henderson gets from investors? "These are big markets, this takes a lot of capital — are you just going to...

The biggest question Apogee Therapeutics CEO Michael Henderson gets from investors? "These are big markets, this takes a lot of capital — are you just going to dilute us every time you have data?" Henderson said ...